Weaver Richard J, Betts Catherine, Blomme Eric A G, Gerets Helga H J, Gjervig Jensen Klaus, Hewitt Philip G, Juhila Satu, Labbe Gilles, Liguori Michael J, Mesens Natalie, Ogese Monday O, Persson Mikael, Snoeys Jan, Stevens James L, Walker Tracy, Park B Kevin
a Research & Biopharmacy, Institut de Recherches Internationales Servier , Suresnes , France.
b Pathology Sciences, Drug Safety and Metabolism , AstraZeneca R&D , Cambridge , UK.
Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):767-782. doi: 10.1080/17425255.2017.1341489. Epub 2017 Jun 28.
The liver is an important target for drug-induced toxicities. Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue for drug development. Areas Covered: The current state of the science, understanding and application of test systems in use for the detection of drug-induced cytotoxicity, mitochondrial toxicity, cholestasis and inflammation is summarized. The test systems highlighted herein cover mostly in vitro and some in vivo models and endpoint measurements used in the assessment of small molecule toxic liabilities. Opportunities for research efforts in areas necessitating the development of specific tests and improved mechanistic understanding are highlighted. Expert Opinion: Use of in vitro test systems for safety optimization will remain a core activity in drug discovery. Substantial inroads have been made with a number of assays established for human Drug-induced Liver Injury. There nevertheless remain significant gaps with a need for improved in vitro tools and novel tests to address specific mechanisms of human Drug-Induced Liver Injury. Progress in these areas will necessitate not only models fit for application, but also mechanistic understanding of how chemical insult on the liver occurs in order to identify translational and quantifiable readouts for decision-making.
肝脏是药物诱导毒性的重要靶点。早期检测肝毒性药物需要使用特征明确的测试系统,但目前所采用测试方法的知识、差距和局限性仍是药物研发中的一个重要问题。涵盖领域:总结了用于检测药物诱导的细胞毒性、线粒体毒性、胆汁淤积和炎症的测试系统的科学现状、理解和应用。本文重点介绍的测试系统主要涵盖体外模型以及一些用于评估小分子毒性的体内模型和终点测量方法。强调了在需要开发特定测试和增进机制理解的领域开展研究工作的机会。专家观点:使用体外测试系统进行安全性优化仍将是药物研发中的核心活动。在针对人类药物性肝损伤建立的一些检测方法方面已取得了重大进展。然而,仍存在重大差距,需要改进体外工具和新型测试方法以解决人类药物性肝损伤的特定机制。这些领域的进展不仅需要适用的模型,还需要对肝脏化学损伤的发生机制有深入理解,以便确定用于决策的可转化和可量化的读数。